Free Trial

Annexon, Inc. (NASDAQ:ANNX) Director Purchases $10,122.90 in Stock

Annexon logo with Medical background

Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director William H. Carson purchased 4,115 shares of the firm's stock in a transaction dated Monday, June 30th. The shares were acquired at an average cost of $2.46 per share, with a total value of $10,122.90. Following the completion of the purchase, the director directly owned 29,715 shares in the company, valued at approximately $73,098.90. This represents a 16.07% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Annexon Price Performance

NASDAQ ANNX traded up $0.15 on Friday, hitting $2.96. 1,884,073 shares of the stock were exchanged, compared to its average volume of 1,455,587. The business's fifty day moving average is $2.20 and its 200 day moving average is $2.85. Annexon, Inc. has a 52 week low of $1.29 and a 52 week high of $7.85. The company has a market capitalization of $324.19 million, a PE ratio of -2.50 and a beta of 1.30.

Annexon (NASDAQ:ANNX - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.07). Analysts predict that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Needham & Company LLC decreased their price objective on Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. HC Wainwright decreased their price target on Annexon from $20.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th.

Read Our Latest Report on Annexon

Institutional Trading of Annexon

Hedge funds have recently made changes to their positions in the business. Alpine Global Management LLC acquired a new position in shares of Annexon during the 1st quarter worth approximately $49,000. Forefront Analytics LLC boosted its position in Annexon by 74.0% during the first quarter. Forefront Analytics LLC now owns 28,591 shares of the company's stock worth $55,000 after purchasing an additional 12,158 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of Annexon in the fourth quarter valued at $59,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Annexon by 164.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,026 shares of the company's stock valued at $66,000 after purchasing an additional 21,143 shares during the last quarter. Finally, Hsbc Holdings PLC raised its position in shares of Annexon by 19.9% in the first quarter. Hsbc Holdings PLC now owns 36,935 shares of the company's stock valued at $73,000 after purchasing an additional 6,136 shares during the period.

Annexon Company Profile

(Get Free Report)

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

Featured Stories

Insider Buying and Selling by Quarter for Annexon (NASDAQ:ANNX)

Should You Invest $1,000 in Annexon Right Now?

Before you consider Annexon, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.

While Annexon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines